Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer
作者： Takeo Fujii , Naoko Matsuda , Miho Kono , Kenichi Harano , Huiqin Chen
DOI: 10.1016/J.EJCA.2017.11.015
关键词: Metastatic breast cancer 、 Multivariate analysis 、 High rate 、 Somatic cell 、 Gene profile 、 Internal medicine 、 Medicine 、 Breast cancer 、 Systemic therapy 、 Oncology 、 Pik3ca mutation
摘要: Abstract Background Understanding the biology of breast cancer is important for guiding treatment strategies and revealing resistance mechanisms. Our objectives were to investigate relationship between previous systemic therapy exposure mutational spectrum in metastatic identify clinicopathological factors associated with identified frequent somatic mutations. Methods Archival tissues patients subjected hotspot molecular testing by next-generation sequencing. The variables that significantly differed (P Results A total 922 included analysis. In multivariate analysis, before (N = 186) was a higher rate TP53 PIK3CA mutations compared lack Conclusion Systemic an independent risk factor high rates mutation, which suggests importance samples after accurately assess It worth gene profile when tumours become resistant treatments.
sci-hub.se 参考文章(27)
Toru Mukohara, PI3K mutations in breast cancer: prognostic and therapeutic implications Breast Cancer: Targets and Therapy. ,vol. 7, pp. 111- 123 ,(2015) , 10.2147/BCTT.S60696
Ezzeldin M. Ibrahim, Ghieth A. Kazkaz, Mubarak M. Al-Mansour, Meteb E. Al-Foheidi, The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis Breast Cancer Research and Treatment. ,vol. 152, pp. 463- 476 ,(2015) , 10.1007/S10549-015-3480-6
Hans P. Eikesdal, Stian Knappskog, Turid Aas, Per E. Lønning, TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta Oncologica. ,vol. 53, pp. 1347- 1355 ,(2014) , 10.3109/0284186X.2014.922215
Kevin D. Courtney, Ryan B. Corcoran, Jeffrey A. Engelman, The PI3K Pathway As Drug Target in Human Cancer Journal of Clinical Oncology. ,vol. 28, pp. 1075- 1083 ,(2010) , 10.1200/JCO.2009.25.3641
Jeffrey A. Engelman, Ji Luo, Lewis C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nature Reviews Genetics. ,vol. 7, pp. 606- 619 ,(2006) , 10.1038/NRG1879
José Baselga, Javier Cortés, Seock-Ah Im, Emma Clark, Graham Ross, Astrid Kiermaier, Sandra M. Swain, Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 32, pp. 3753- 3761 ,(2014) , 10.1200/JCO.2013.54.5384
M Hollstein, D Sidransky, B Vogelstein, C. Harris, p53 mutations in human cancers Science. ,vol. 253, pp. 49- 53 ,(1991) , 10.1126/SCIENCE.1905840
Dejan Juric, Pau Castel, Malachi Griffith, Obi L. Griffith, Helen H. Won, Haley Ellis, Saya H. Ebbesen, Benjamin J. Ainscough, Avinash Ramu, Gopa Iyer, Ronak H. Shah, Tiffany Huynh, Mari Mino-Kenudson, Dennis Sgroi, Steven Isakoff, Ashraf Thabet, Leila Elamine, David B. Solit, Scott W. Lowe, Cornelia Quadt, Malte Peters, Adnan Derti, Robert Schegel, Alan Huang, Elaine R. Mardis, Michael F. Berger, José Baselga, Maurizio Scaltriti, Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor Nature. ,vol. 518, pp. 240- 244 ,(2015) , 10.1038/NATURE13948
Bart Vanhaesebroeck, Julie Guillermet-Guibert, Mariona Graupera, Benoit Bilanges, The emerging mechanisms of isoform-specific PI3K signalling Nature Reviews Molecular Cell Biology. ,vol. 11, pp. 329- 341 ,(2010) , 10.1038/NRM2882
L. C. Cantley, The Phosphoinositide 3-Kinase Pathway Science. ,vol. 296, pp. 1655- 1657 ,(2002) , 10.1126/SCIENCE.296.5573.1655